Refine
Has Fulltext
- yes (54)
Is part of the Bibliography
- yes (54)
Year of publication
Document Type
- Journal article (53)
- Conference Proceeding (1)
Language
- English (54) (remove)
Keywords
- blood vessel (3)
- inflammation (3)
- organoid (3)
- 18F-FDG (2)
- Myokarditis (2)
- PET (2)
- TGFβ signaling (2)
- angiogenesis (2)
- cancer (2)
- diabetic retinopathy (2)
- extracellular matrix (2)
- in vitro (2)
- macrophages (2)
- medical research (2)
- mouse (2)
- mucoepidermoid carcinoma (2)
- multiple sclerosis (2)
- myocarditis (2)
- neurotrophins (2)
- organoids (2)
- oxidative stress (2)
- photon-counting (2)
- pleomorphic adenoma (2)
- positron emission tomography (2)
- preclinical research (2)
- retinitis pigmentosa (2)
- translational research (2)
- tumor microenvironment (2)
- vasculogenesis (2)
- 3D image analysis (1)
- AZD4547 (1)
- B cells (1)
- CEA (1)
- CEACAM1 (1)
- CMV (1)
- COPD (1)
- CT angiography (1)
- CXCL12-abundant reticular (CAR)-cells (1)
- Cancellous bone (1)
- Cancer models (1)
- Cancer therapeutic resistance (1)
- Chirurgie (1)
- Cone-beam computed tomography (1)
- DNA methylation (1)
- Developmental biology (1)
- EBV (1)
- ECM (1)
- ELISPOT (1)
- ER-Stress (1)
- Elbow (1)
- Elbow joint (1)
- Endoplasmic-Reticulum Stress (1)
- FGFR signaling (1)
- Hematopoietic Stem (1)
- Heme-regulated inhibitor (1)
- Human Muse Cells (1)
- II type-2 receptor (1)
- IL6 (1)
- MAP kinase pathway (1)
- MS (1)
- Messenger-RNAs (1)
- Multidetector computed tomography (1)
- Mycobacterium tuberculosis (1)
- NF-kappa-B (1)
- Neural Differentiation (1)
- OXPHOS (1)
- PIK3R1 (1)
- Quality-control (1)
- ROS (1)
- Rv3034c (1)
- SARS-CoV-2 (1)
- SP-fixation (1)
- Stem cells (1)
- TNF-α (1)
- TTS (1)
- Targeted therapies (1)
- Transcription factor NRF1 (1)
- Translation Initiation (1)
- Tumour angiogenesis (1)
- VPP mouse model (1)
- X-ray computed (1)
- abdominal imaging (1)
- acetyltransferase (1)
- acinic cell carcinoma (1)
- adenoid cystic carcinoma (ACC) (1)
- adipose tissue (1)
- adipose-derived stromal cells (1)
- adventitia (1)
- age-related macular degeneration (1)
- aging (1)
- anatomy (1)
- angiotensin II (1)
- animal models (1)
- anti‐aging (1)
- aorta ring (1)
- aortic adventitia (1)
- assembloid (1)
- autoimmunity (1)
- beta-aminopropionitrile (1)
- bioprinting (1)
- blood pressure (1)
- bone (1)
- bone marrow-derived monocytes (1)
- brain-retina axis (1)
- breast cancer cells (1)
- breast cancer model (1)
- cable-clamp implants (1)
- cadaver multiorgan preservation (1)
- cancellous bone (1)
- cancer therapy (1)
- cardiac hyperthrophy (1)
- cardiovascular MRI (1)
- cell biology (1)
- chemotherapy (CH) (1)
- chromatin (1)
- chronic kidney disease (1)
- computed tomography angiography (CTA) (1)
- continuous extracorporeal femoral perfusion model (1)
- contractility (1)
- convolution kernel (1)
- cytokines (1)
- developmental biology (1)
- diabetes mellitus (1)
- diabetic nephropathy (1)
- diagnostic markers (1)
- differential expression (1)
- digital subtraction angiography (DSA) (1)
- dilated cardiomyopathy with ataxia (1)
- dovitinib (1)
- drug transport (1)
- editorial (1)
- electron microscopy (1)
- emphysema (1)
- endothelial cell infection (1)
- epithelial salivary gland (1)
- experimental models of disease (1)
- expression (1)
- extracellular matrix disorganisation (1)
- extracorporeal membrane oxygenation (1)
- extrusion of hiMPC-containing bioinks alginate + collagen type I (1)
- factor binding profiles (1)
- femoral arteries (1)
- ferroptosis (1)
- fracture (1)
- genetics (1)
- hACE2 (1)
- heart (1)
- heart failure (1)
- heart-brain axis (1)
- hematopoietic (1)
- high contrast (1)
- histone H1 (1)
- homebox genes (1)
- human endothelial cells (1)
- human iPSC-derived mesodermal cells (hiMPCs) (1)
- human induced pluripotent stem cells (1)
- human neurons (1)
- human osteosarcoma xenografts (1)
- hyaluronic acid (1)
- hypoxia (1)
- hypoxia inducible factor 1 (1)
- immunohistochemistry (1)
- immunotherapy (1)
- in-situ hybridization (1)
- induced neural stem cells (1)
- induced pluripotent stem cells (1)
- intravascular ultrasound (IVUS) (1)
- ischemic stroke (1)
- large animal models (1)
- light sheet fluorescence microscopy (1)
- lipids (1)
- mRNA (1)
- malignancy (1)
- megakaryocytes (1)
- meninges (1)
- mesenchymal stem cells (1)
- mesenchymal stromal cells (1)
- mesodermal organoid (1)
- metabolism (1)
- metastasis (1)
- mice (1)
- microRNA (1)
- microglia (1)
- microvascular complications (1)
- microvasculature (1)
- mild hypothermia (1)
- mitochondria (1)
- molecular biology (1)
- multilayered vessel wall with intimate, media and adventitia (1)
- musculoskeletal system (1)
- mutations (1)
- myelin (1)
- myeloid (1)
- myocardial infarction (1)
- neural (1)
- neural crest (1)
- neural organoid (1)
- neuro-/photoreceptor degeneration (1)
- neurodegeneration (1)
- neuroimmunology (1)
- neuroinflammation (1)
- neuroprotective pathways (1)
- novel human cadaveric perfusion model (1)
- oligodendrocytes (1)
- open-access database (1)
- optical clearing (1)
- pancreatic cancer (1)
- parotid gland (1)
- peripheral nervous system (1)
- peroxisome (1)
- peroxisomes (1)
- personalized treatment (1)
- phosphatidylinositol (1)
- photon-counting computed tomography (CT) (1)
- pig (1)
- post-mortem heart recovery (1)
- probe level data (1)
- progenitor (1)
- progenitor cells (1)
- pubic symphysis (1)
- pulmonary hypertension (1)
- radiation (1)
- radiotherapy (1)
- rat heart (1)
- reactive oxygen species (1)
- research infrastructure (1)
- resident CD34-positive cells (1)
- retina (1)
- salivary (1)
- salivary gland (1)
- salivary gland tumors (1)
- sasculature (1)
- sensory ganglia (1)
- sensory neuron (1)
- serial block face EM (1)
- signaling (1)
- small pixel effect (1)
- solid tumors (1)
- spectral shaping (1)
- spheroids (1)
- stroma (1)
- synapse (1)
- synaptic vesicles (1)
- tin prefiltration (1)
- tomography (1)
- transcapillary pressure gradient (1)
- transmission electron microscopy (1)
- tube formation (1)
- tumor (1)
- tumor spheroids (1)
- tumor-vessel wall-interface model (1)
- tumors (1)
- ultra-low-dose CT (1)
- ultrahigh resolution (1)
- ultrahigh-field MRI (1)
- urinary calculi (1)
- vascular biofabrication (1)
- vascular network and hierarchical organized vessels (1)
- vascular normalization (1)
- vascular structure (1)
- vascular wall stem and progenitor cells (1)
- vascularization model (1)
- vasculature (1)
- xerostomia (1)
Institute
- Institut für Anatomie und Zellbiologie (54)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (9)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (5)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (4)
- Medizinische Klinik und Poliklinik I (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (3)
- Institut für Pharmakologie und Toxikologie (3)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (2)
- Graduate School of Life Sciences (2)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
3D cell culture models which closely resemble real human tissues are of high interest for disease modelling, drug screening as well as a deeper understanding of human developmental biology. Such structures are termed organoids. Within the last years, several human organoid models were described. These are usually stem cell derived, arise by self-organization, mimic mechanisms of normal tissue development, show typical organ morphogenesis and recapitulate at least some organ specific functions. Many tissues have been reproduced in vitro such as gut, liver, lung, kidney and brain. The resulting entities can be either derived from an adult stem cell population, or generated from pluripotent stem cells using a specific differentiation protocol. However, many organoid models only recapitulate the organs parenchyma but are devoid of stromal components such as blood vessels, connective tissue and inflammatory cells. Recent studies show that the incorporation of endothelial and mesenchymal cells into organoids improved their maturation and might be required to create fully functional micro-tissues, which will allow deeper insights into human embryogenesis as well as disease development and progression. In this review article, we will summarize and discuss recent works trying to incorporate stromal components into organoids, with a special focus on neural organoid models.
Aging is an independent risk factor for cardiovascular diseases and therefore of particular interest for the prevention of cardiovascular events. However, the mechanisms underlying vascular aging are not well understood. Since carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) is crucially involved in vascular homeostasis, we sought to identify the role of CEACAM1 in vascular aging. Using human internal thoracic artery and murine aorta, we show that CEACAM1 is upregulated in the course of vascular aging. Further analyses demonstrated that TNF‐α is CEACAM1‐dependently upregulated in the aging vasculature. Vice versa, TNF‐α induces CEACAM1 expression. This results in a feed‐forward loop in the aging vasculature that maintains a chronic pro‐inflammatory milieu. Furthermore, we demonstrate that age‐associated vascular alterations, that is, increased oxidative stress and vascular fibrosis, due to increased medial collagen deposition crucially depend on the presence of CEACAM1. Additionally, age‐dependent upregulation of vascular CEACAM1 expression contributes to endothelial barrier impairment, putatively via increased VEGF/VEGFR‐2 signaling. Consequently, aging‐related upregulation of vascular CEACAM1 expression results in endothelial dysfunction that may promote atherosclerotic plaque formation in the presence of additional risk factors. Our data suggest that CEACAM1 might represent an attractive target in order to delay physiological aging and therefore the transition to vascular disorders such as atherosclerosis.
Organoids derived from human pluripotent stem cells are interesting models to study mechanisms of morphogenesis and promising platforms for disease modeling and drug screening. However, they mostly remain incomplete as they lack stroma, tissue resident immune cells and in particular vasculature, which create important niches during development and disease. We propose, that the directed incorporation of mesodermal progenitor cells (MPCs) into organoids will overcome the aforementioned limitations. In order to demonstrate the feasibility of the method, we generated complex human tumor as well as neural organoids. We show that the formed blood vessels display a hierarchic organization and mural cells are assembled into the vessel wall. Moreover, we demonstrate a typical blood vessel ultrastructure including endothelial cell-cell junctions, a basement membrane as well as luminal caveolae and microvesicles. We observe a high plasticity in the endothelial network, which expands, while the organoids grow and is responsive to anti-angiogenic compounds and pro-angiogenic conditions such as hypoxia. We show that vessels within tumor organoids connect to host vessels following transplantation. Remarkably, MPCs also deliver Iba1\(^+\) cells that infiltrate the neural tissue in a microglia-like manner.
The Best for the Most Important: Maintaining a Pristine Proteome in Stem and Progenitor Cells
(2019)
Pluripotent stem cells give rise to reproductively enabled offsprings by generating progressively lineage-restricted multipotent stem cells that would differentiate into lineage-committed stem and progenitor cells. These lineage-committed stem and progenitor cells give rise to all adult tissues and organs. Adult stem and progenitor cells are generated as part of the developmental program and play critical roles in tissue and organ maintenance and/or regeneration. The ability of pluripotent stem cells to self-renew, maintain pluripotency, and differentiate into a multicellular organism is highly dependent on sensing and integrating extracellular and extraorganismal cues. Proteins perform and integrate almost all cellular functions including signal transduction, regulation of gene expression, metabolism, and cell division and death. Therefore, maintenance of an appropriate mix of correctly folded proteins, a pristine proteome, is essential for proper stem cell function. The stem cells' proteome must be pristine because unfolded, misfolded, or otherwise damaged proteins would interfere with unlimited self-renewal, maintenance of pluripotency, differentiation into downstream lineages, and consequently with the development of properly functioning tissue and organs. Understanding how various stem cells generate and maintain a pristine proteome is therefore essential for exploiting their potential in regenerative medicine and possibly for the discovery of novel approaches for maintaining, propagating, and differentiating pluripotent, multipotent, and adult stem cells as well as induced pluripotent stem cells. In this review, we will summarize cellular networks used by various stem cells for generation and maintenance of a pristine proteome. We will also explore the coordination of these networks with one another and their integration with the gene regulatory and signaling networks.
Aims: Although mortality rate is very high, diagnosis of acute myocarditis remains challenging with conventional tests. We aimed to elucidate the potential role of longitudinal 2-Deoxy-2-\(^{18}\)F-fluoro-D-glucose (\(^{18}\)F-FDG) positron emission tomography (PET) inflammation monitoring in a rat model of experimental autoimmune myocarditis.
Methods and results: Autoimmune myocarditis was induced in Lewis rats by immunizing with porcine cardiac myosin emulsified in complete Freund’s adjuvant. Time course of disease was assessed by longitudinal \(^{18}\)F-FDG PET imaging. A correlative analysis between in- and ex vivo \(^{18}\)F-FDG signalling and macrophage infiltration using CD68 staining was conducted. Finally, immunohistochemistry analysis of the cell-adhesion markers CD34 and CD44 was performed at different disease stages determined by longitudinal \(^{18}\)F-FDG PET imaging. After immunization, myocarditis rats revealed a temporal increase in 18F-FDG uptake (peaked at week 3), which was followed by a rapid decline thereafter. Localization of CD68 positive cells was well correlated with in vivo \(^{18}\)F-FDG PET signalling (R\(^2\) = 0.92) as well as with ex vivo 18F-FDG autoradiography (R\(^2\) = 0.9, P < 0.001, respectively). CD44 positivity was primarily observed at tissue samples obtained at acute phase (i.e. at peak 18F-FDG uptake), while CD34-positive staining areas were predominantly identified in samples harvested at both sub-acute and chronic phases (i.e. at \(^{18}\)F-FDG decrease).
Conclusion: \(^{18}\)F-FDG PET imaging can provide non-invasive serial monitoring of cardiac inflammation in a rat model of acute myocarditis.
LOX-catalyzed collagen stabilization is a proximal cause for intrinsic resistance to chemotherapy
(2018)
The potential of altering the tumor ECM to improve drug response remains fairly unexplored. To identify targets for modification of the ECM aiming to improve drug response and overcome resistance, we analyzed expression data sets from pre-treatment patient cohorts. Cross-evaluation identified a subset of chemoresistant tumors characterized by increased expression of collagens and collagen-stabilizing enzymes. We demonstrate that strong collagen expression and stabilization sets off a vicious circle of self-propagating hypoxia, malignant signaling, and aberrant angiogenesis that can be broken by an appropriate auxiliary intervention: Interfering with collagen stabilization by inhibition of lysyl oxidases significantly enhanced response to chemotherapy in various tumor models, even in metastatic disease. Inhibition of collagen stabilization by itself can reduce or enhance tumor growth depending on the tumor type. The mechanistical basis for this behavior is the dependence of the individual tumor on nutritional supply on one hand and on high tissue stiffness for FAK signaling on the other.
There is a largely divergent body of literature regarding the relationship between Epstein-Barr virus (EBV) infection and brain inflammation in multiple sclerosis (MS). Here, we tested MS patients during relapse (n = 11) and in remission (n = 19) in addition to n = 22 healthy controls to study the correlation between the EBV- and brain-specific B cell response in the blood by enzyme-linked immunospot (ELISPOT) and enzyme-linked immunosorbent assay (ELISA). Cytomegalovirus (CMV) was used as a control antigen tested in n = 16 MS patients during relapse and in n = 35 patients in remission. Over the course of the study, n = 16 patients were untreated, while n = 33 patients received immunomodulatory therapy. The data show that there was a moderate correlation between the frequencies of EBV- and brain-reactive B cells in MS patients in remission. In addition we could detect a correlation between the B cell response to EBV and disease activity. There was no evidence of an EBV reactivation. Interestingly, there was also a correlation between the frequencies of CMV- and brain-specific B cells in MS patients experiencing an acute relapse and an elevated B cell response to CMV was associated with higher disease activity. The trend remained when excluding seronegative subjects but was non-significant. These data underline that viral infections might impact the immunopathology of MS, but the exact link between the two entities remains subject of controversy.
B cell aggregates in the central nervous system (CNS) have been associated with rapid disease progression in patients with multiple sclerosis (MS). Here we demonstrate a key role of carcinoembryogenic antigen-related cell adhesion molecule1 (CEACAM1) in B cell aggregate formation in MS patients and a B cell-dependent mouse model of MS. CEACAM1 expression was increased on peripheral blood B cells and CEACAM1\(^+\) B cells were present in brain infiltrates of MS patients. Administration of the anti-CEACAM1 antibody T84.1 was efficient in blocking aggregation of B cells derived from MS patients. Along these lines, application of the monoclonal anti-CEACAM1 antibody mCC1 was able to inhibit CNS B cell aggregate formation and significantly attenuated established MS-like disease in mice in the absence of any adverse effects. CEACAM1 was co-expressed with the regulator molecule T cell immunoglobulin and mucin domain −3 (TIM-3) on B cells, a novel molecule that has recently been described to induce anergy in T cells. Interestingly, elevated coexpression on B cells coincided with an autoreactive T helper cell phenotype in MS patients. Overall, these data identify CEACAM1 as a clinically highly interesting target in MS pathogenesis and open new therapeutic avenues for the treatment of the disease.
Tumors are characterized by a rigid, highly cross-linked extracellular matrix (ECM), which impedes homogeneous drug distribution and potentially protects malignant cells from exposure to therapeutics. Lysyl oxidases are major contributors to tissue stiffness and the elevated expression of these enzymes observed in most cancers might influence drug distribution and efficacy. We examined the effect of lysyl oxidases on drug distribution and efficacy in 3D in vitro assay systems. In our experiments elevated lysyl oxidase activity was responsible for reduced drug diffusion under hypoxic conditions and consequently impaired cytotoxicity of various chemotherapeutics. This effect was only observed in 3D settings but not in 2D-cell culture, confirming that lysyl oxidases affect drug efficacy by modification of the ECM and do not confer a direct desensitizing effect. Both drug diffusion and efficacy were strongly enhanced by inhibition of lysyl oxidases. The results from the in vitro experiments correlated with tumor drug distribution in vivo, and predicted response to therapeutics in murine tumor models. Our results demonstrate that lysyl oxidase activity modulates the physical barrier function of ECM for small molecule drugs influencing their therapeutic efficacy. Targeting this process has the potential to significantly enhance therapeutic efficacy in the treatment of malignant diseases.